Remarkably, a recent study demonstrated that an RNA editing strategy could rescue gene duplication in a mouse model of MDS and nonhuman primates, providing a potential strategy for treating MECP2-related and other dosage-sensitive diseases [237]. This evidence concerns the gene MECP2 and myelodysplastic syndrome.